(Q35784057)

10 August 2017

1 reference

title

A review of the proteasome inhibitor bortezomib in multiple myeloma (English)

1 reference

10 August 2017

Paul G Richardson

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

1321-1331

1 reference

Management of multiple myeloma: a systematic review and critical appraisal of published studies

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Proteasome inhibition: a new strategy in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

The ubiquitin system for protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1321

10.1517/14656566.5.6.1321

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference